This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

10 Alzheimer's Disease Treatment Stocks

Elan and Transition Therapeutics
Drug: ELND-005
Drug type: Amyloid beta
Stage: Phase II
On Aug. 9, Elan and Transition announced plans to move ELND-005 into phase III studies despite what appears to be mixed results from a recently completed phase II study in mild to moderate Alzheimer's patients. The phase II study of ELND-005 failed to meet its cognitive and functional endpoints overall but the companies said the drug had an effect on amyloid-beta proteins in the spinal fluid and showed some clinical benefit in a subgroup of patients.

Eli Lilly
Drug: Solanezumab
Drug type: Amyloid beta immunotherapy
Stage: Phase III
Two phase III studies of solanezumab are currently enrolling patients with mild to moderate Alzheimer's patients. Results are expected in 2012-2013.

Bristol-Myers Squibb (BMY - Get Report)
Drug: BMS-708163
Drug type: Gamma secretase inhibitor
Stage: Phase II
BMS-708163 belongs to the same class of gamma secretase inhibitors as Lilly's discontinued drug semagacestat. Top-line results from the ongoing phase II study of '708163 in patients with mild to moderate Alzheimer's are expected in the fourth quarter.

Baxter (BAX - Get Report)
Drug: Gammagard
Drug type: Amyloid Beta
Stage: Phase III
Baxter expects to complete enrollment in the phase III Gammagard study by the end of the year, with results likely in 2012. The phase III study hopes to confirm positive results seen in phase II studies of Gammagard.
2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
BMY $67.85 1.30%
BAX $37.98 0.88%
JNJ $102.31 1.10%
LLY $85.84 4.60%
PRAN $0.95 -3.10%


Chart of I:DJI
DOW 17,835.27 +115.35 0.65%
S&P 500 2,093.11 +12.70 0.61%
NASDAQ 5,135.7820 +27.1160 0.53%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs